Legacy Healthcare Announces EMA Validation of Marketing Authorisation Application (MAA) for Coacillium for the treatment of Moderate and Severe Alopecia Areata in Children and Adolescents ...Middle East

PR Newswire - News
Legacy Healthcare Announces EMA Validation of Marketing Authorisation Application (MAA) for Coacillium for the treatment of Moderate and Severe Alopecia Areata in Children and Adolescents
LAUSANNE, Switzerland, June 19, 2023 /PRNewswire/ -- Legacy Healthcare (or the "Company"), today announced that its Marketing Authorisation Application (MAA) to the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for Coacillium for the treatment of...

Hence then, the article about legacy healthcare announces ema validation of marketing authorisation application maa for coacillium for the treatment of moderate and severe alopecia areata in children and adolescents was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Legacy Healthcare Announces EMA Validation of Marketing Authorisation Application (MAA) for Coacillium for the treatment of Moderate and Severe Alopecia Areata in Children and Adolescents )

Apple Storegoogle play

Last updated :

Also on site :